181 results on '"Ducray F"'
Search Results
2. Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm
3. The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches
4. OS02.4.A Molecular characterization of adult cerebellar glioblastomas identifies distinct prognosis subgroups
5. OS02.6.A The TeloDIAG: How telomeric parameters can help in glioma rapid diagnosis and liquid biopsies approaches
6. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)
7. P14.12 Gyriform infiltration as imaging biomarker for adult diffuse astrocytic glioma, IDH wildtype, with molecular features of glioblastoma
8. RSL24D1 sustains steady-state ribosome biogenesis and pluripotency translational programs in embryonic stem cells
9. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
10. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
11. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study
12. JS1.2 Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era
13. OS9.3 Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusion
14. OS8.4 Impact of brain invasion assessment on outcome in intracranial grade II meningiomas
15. P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study
16. P14.33 Adult brainstem gliomas in neurofibromatosis type 1 (NF1)
17. OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults
18. P13.02 Conventional MRI radiomics in the diagnosis of early- and pseudo-progression
19. P14.13 Incidence of pseudoprogression in high-grade IDH-mutant gliomas
20. OS5.4 Characteristics of adult diffuse H3K27M-mutant gliomas at recurrence
21. OS9.2 Radiomics analysis of lower-grade gliomas, a POLA Network study
22. PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
23. P14.88 Comparison of SNaPshot PCR and digital droplet PCR for the identification of TERT promoter in non-diagnostic biopsies from glioma patients
24. P04.18 Management of diffuse gliomas using hypnosis-aided awake surgery: oncological and functional preliminary results in a series of 16 cases
25. P01.120 Importance of systematic TERT promoter and IDH mutations screening in non-diagnostic biopsies from patients with a suspected glioma
26. OS3.3 Radiological characteristics and natural history of adult IDH wild type astrocytomas with TERT promoter mutations
27. OS2.4 Angiotensin II Receptor Blockers, steroids and radiotherapy in glioblastoma - A randomized multicenter trial (ASTER Trial). An ANOCEF Study
28. P10.14 Long-term impact of Temozolomide on 1p19q codeleted oligodendrogliomas growth kinetics
29. OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas
30. Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
31. 400PD - Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study
32. P08.39 Characteristics of adults’ gliomas with H3-K27M mutations
33. OS6.7 Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies: results from the IasON trial
34. P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients
35. P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study
36. P07.02 Diagnostic pitfalls in brainstem lesions mimicking gliomas in adults
37. P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study
38. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
39. Monitoring and characterization of bacterial populations of two biological air filters during the start up phase
40. O10.02 * MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS
41. P17.01 * CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY
42. O8.08 * CIC MUTATION IS A POOR PROGNOSIS FACTOR IN 1P19Q CODELETED GLIOMAS, ASSOCIATED TO AN UP-REGULATION OF PROLIFERATION PATHWAYS
43. O3.03 * THE SPECTRUM OF LATE PAROXYSMAL NEUROLOGICAL SYNDROMES AFTER BRAIN IRRADIATION
44. Pontine infarction responsible for wall-eyed bilateral internuclear ophthalmoplegia syndrome
45. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951
46. Peri-ictal pseudoprogression in patients with brain tumor
47. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
48. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas
49. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies
50. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.